EP3M Summit 2026 Set to Transform Biopharma Decision-Making Processes
The highly anticipated 2026 EP3M Summit organized by the Cambridge Healthtech Institute (CHI) will take place on September 29–30, 2026, in Boston as well as virtually. Celebrating its twentieth edition, this summit aims to gather senior leaders from the pharmaceutical and biotechnology fields to delve into practical strategies regarding portfolio governance, analytics, prioritization, and decision-making in an increasingly complex landscape.
As the biopharma sector continues to face significant pressures to enhance portfolio value amidst scientific ambiguity and resource limitations, this year’s agenda emphasizes aligning strategic execution with data utilization and artificial intelligence (AI) to refine portfolio decisions. The summit's multifaceted program includes keynote sessions, executive case studies, panel discussions, and interactive roundtables, providing a platform for leaders to exchange insights into improving portfolio prioritization, governance, decision intelligence, and resource allocation across research and development (R&D).
Bridget Kotelly, the Senior Conference Director at CHI, remarked, "Today’s portfolio leaders must strike a delicate balance between swift decision-making and the challenges posed by limited resources and rising organizational complexity. The EP3M Summit offers a unique opportunity to explore how decisions unfold within pharmaceutical companies, while fostering the sharing of practical frameworks and lessons that can enhance portfolio performance and decision quality."
One of the summit's highlights will be a keynote from Noel Sobelman, Partner at Accel Management Group, who will discuss his insights from his new book, focusing on Innovation Portfolio Management and its connection to strategic execution. Additionally, Sobelman will moderate a panel featuring executives from notable brands such as Novartis, Biogen, and Zentalis Pharmaceuticals, discussing the real-world application of innovation portfolio management.
A fresh addition for 2026 is the pre-conference workshop titled Inside the Portfolio Committee: Making R&D Investment Decisions Under Uncertainty. Led by Joe Stalder, Vice President at Zentalis Pharmaceuticals, and Magnus Ytterstad, Product Owner of Portfolio Management at Captario, this workshop will immerse participants in a simulated pharmaceutical portfolio decision environment, incorporating strategic discussions and hands-on exercises to bolster decision-making skills.
The summit will feature participation from top industry leaders including AbbVie, GSK, Bristol Myers Squibb, Eli Lilly, Flagship Pioneering, Merck, Sanofi, and more. Key topics to be explored include:
Registration for the event is currently open. To take advantage of early-bird savings, attendees are encouraged to register by July 17, 2026. Additional information regarding the full agenda and workshop specifics can be found at EP3MSummit.com.
In summary, the EP3M Summit stands as a pivotal gathering for industry leaders focused on enhancing excellence in project, program, and portfolio management within the biopharma sector. By facilitating valuable discussions around innovative strategies and decision-making processes, this event promises to significantly contribute to the future trajectory of executive decision-making in pharmaceutical and biotechnology sectors.
As the biopharma sector continues to face significant pressures to enhance portfolio value amidst scientific ambiguity and resource limitations, this year’s agenda emphasizes aligning strategic execution with data utilization and artificial intelligence (AI) to refine portfolio decisions. The summit's multifaceted program includes keynote sessions, executive case studies, panel discussions, and interactive roundtables, providing a platform for leaders to exchange insights into improving portfolio prioritization, governance, decision intelligence, and resource allocation across research and development (R&D).
Bridget Kotelly, the Senior Conference Director at CHI, remarked, "Today’s portfolio leaders must strike a delicate balance between swift decision-making and the challenges posed by limited resources and rising organizational complexity. The EP3M Summit offers a unique opportunity to explore how decisions unfold within pharmaceutical companies, while fostering the sharing of practical frameworks and lessons that can enhance portfolio performance and decision quality."
One of the summit's highlights will be a keynote from Noel Sobelman, Partner at Accel Management Group, who will discuss his insights from his new book, focusing on Innovation Portfolio Management and its connection to strategic execution. Additionally, Sobelman will moderate a panel featuring executives from notable brands such as Novartis, Biogen, and Zentalis Pharmaceuticals, discussing the real-world application of innovation portfolio management.
A fresh addition for 2026 is the pre-conference workshop titled Inside the Portfolio Committee: Making R&D Investment Decisions Under Uncertainty. Led by Joe Stalder, Vice President at Zentalis Pharmaceuticals, and Magnus Ytterstad, Product Owner of Portfolio Management at Captario, this workshop will immerse participants in a simulated pharmaceutical portfolio decision environment, incorporating strategic discussions and hands-on exercises to bolster decision-making skills.
The summit will feature participation from top industry leaders including AbbVie, GSK, Bristol Myers Squibb, Eli Lilly, Flagship Pioneering, Merck, Sanofi, and more. Key topics to be explored include:
- - Strategic prioritization and optimizing portfolio value
- - Decision intelligence and portfolio analytics
- - The role of AI in portfolio management
- - Competitive intelligence and governance models
- - Real-world decision-making under uncertainty
Registration for the event is currently open. To take advantage of early-bird savings, attendees are encouraged to register by July 17, 2026. Additional information regarding the full agenda and workshop specifics can be found at EP3MSummit.com.
In summary, the EP3M Summit stands as a pivotal gathering for industry leaders focused on enhancing excellence in project, program, and portfolio management within the biopharma sector. By facilitating valuable discussions around innovative strategies and decision-making processes, this event promises to significantly contribute to the future trajectory of executive decision-making in pharmaceutical and biotechnology sectors.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.